QuidelOrtho Corporation (NASDAQ:QDEL) Stock Has Average Price Target of $13.62

QuidelOrtho Corporation (NASDAQ:QDEL) has been given an average rating of “Reduce” by the six analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $13.62.

A number of brokerages have weighed in on QDEL. JPMorgan Chase & Co. increased their price target on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a research note on Wednesday, July 1st. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Friday, October 9th. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Finally, Citigroup increased their target price on QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th.

QuidelOrtho Stock Performance

NASDAQ:QDEL opened at $13.87 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76. The firm has a market cap of $951.07 million, a PE ratio of 10.44 and a beta of 0.79. The firm has a 50 day simple moving average of $12.91 and a 200-day simple moving average of $13.94. QuidelOrtho has a 1-year low of $9.92 and a 1-year high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. QuidelOrtho’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities analysts expect that QuidelOrtho will post 0.75 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rice Hall James & Associates LLC purchased a new stake in QuidelOrtho in the second quarter valued at approximately $18,628,000. Tejara Capital Ltd acquired a new position in QuidelOrtho during the second quarter worth approximately $2,275,000. Edgestream Partners L.P. purchased a new position in QuidelOrtho during the first quarter worth approximately $1,937,000. Bank of New York Mellon Corp purchased a new position in QuidelOrtho during the second quarter worth approximately $7,720,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in QuidelOrtho during the second quarter worth approximately $44,168,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) develops, manufactures and distributes diagnostic products used by healthcare providers, clinical laboratories and blood-processing organizations. The company’s offerings are designed to support the detection, diagnosis and monitoring of infectious diseases, cardiovascular conditions and other medical conditions.

Its product portfolio includes point-of-care testing systems, molecular diagnostic assays, immunoassays, clinical chemistry and immunodiagnostic platforms, as well as transfusion medicine products.